CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 72 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,868,446 | +746.4% | 62,826 | +357.1% | 0.00% | – |
| Q2 2023 | $220,745 | 0.0% | 13,745 | 0.0% | 0.00% | – |
| Q1 2023 | $220,745 | -53.7% | 13,745 | -47.3% | 0.00% | – |
| Q4 2022 | $477,008 | -99.9% | 26,066 | 0.0% | 0.00% | – |
| Q3 2022 | $511,936,000 | +99.7% | 26,066 | +89.6% | 0.00% | – |
| Q2 2022 | $256,344,000 | -22.3% | 13,745 | -8.5% | 0.00% | – |
| Q1 2022 | $329,711,000 | -49.5% | 15,021 | -34.6% | 0.00% | – |
| Q4 2021 | $652,634,000 | +92.1% | 22,972 | +42.3% | 0.00% | – |
| Q3 2021 | $339,747,000 | +11.7% | 16,140 | 0.0% | 0.00% | – |
| Q2 2021 | $304,239,000 | +37.3% | 16,140 | +11.3% | 0.00% | – |
| Q1 2021 | $221,606,000 | +8.3% | 14,503 | 0.0% | 0.00% | – |
| Q4 2020 | $204,637,000 | +24.3% | 14,503 | +38.1% | 0.00% | – |
| Q3 2020 | $164,582,000 | -71.8% | 10,503 | -68.4% | 0.00% | – |
| Q2 2020 | $582,610,000 | – | 33,254 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |